MedTrace Logo

Health Effects of Salmon Fishmeal in Humans

NCT03764423 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-09-28

No results posted yet for this study

Summary

Diabetes contributes significantly to the burden of disease in Norway and cardiovascular disease is the main cause of mortality.

Both lean and fatty fish are shown to have beneficial health effects. In addition to omega-3 fatty acids, fish contain potential health-promoting components such as taurine, vitamin D, vitamin B12, iodine, selenium and more unspecified components such as bioactive peptides. With the expected growth in the aquaculture sector, more protein-rich by-products will become available.

The overall aim of this project is to investigate the health beneficial effects of fish protein in the form of salmon fishmeal in a human intervention study with regard to metabolic risk markers.

We will include subjects with impaired glucose tolerance to a randomized controlled parallel study. The subjects will receive capsules with fishmeal or placebo.

Conditions

  • Impaired Glucose Tolerance

Interventions

DIETARY_SUPPLEMENT

Salmon fishmeal

Salmon fishmeal with high protein content

DIETARY_SUPPLEMENT

Microcrystalline cellulose

Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.

Sponsors & Collaborators

  • University of Oslo

    lead OTHER

Principal Investigators

  • Kirsten Holven, Professor · University of Oslo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-14
Primary Completion
2019-11-01
Completion
2019-11-01

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03764423 on ClinicalTrials.gov